Daré Bioscience, Inc.
DARE
$2.04
-$0.04-1.92%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.62% | -99.08% | -99.65% | 88.13% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.62% | -99.08% | -99.65% | 88.13% | -- |
| Cost of Revenue | -33.69% | -33.75% | -18.62% | -17.23% | -17.23% |
| Gross Profit | 25.09% | 25.45% | 6.54% | 20.84% | 26.65% |
| SG&A Expenses | -18.99% | -21.78% | -23.12% | -16.98% | -11.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.61% | -29.36% | -30.07% | -42.05% | -27.37% |
| Operating Income | 30.92% | 22.44% | 23.71% | 45.15% | 34.34% |
| Income Before Tax | -158.33% | 94.19% | 86.56% | 91.22% | 81.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -158.33% | 94.19% | 86.56% | 91.22% | 81.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -158.33% | 94.19% | 86.56% | 91.22% | 81.89% |
| EBIT | 30.92% | 22.44% | 23.71% | 45.15% | 34.34% |
| EBITDA | 33.18% | 23.01% | 23.75% | 45.21% | 34.40% |
| EPS Basic | -106.91% | 94.68% | 87.68% | 91.08% | 81.37% |
| Normalized Basic EPS | -119.66% | 92.67% | 85.77% | 91.55% | 81.85% |
| EPS Diluted | -103.59% | 94.22% | 87.27% | 90.76% | 81.05% |
| Normalized Diluted EPS | -117.20% | 92.36% | 85.48% | 91.35% | 81.65% |
| Average Basic Shares Outstanding | 7.94% | 10.72% | 14.14% | 13.58% | 12.32% |
| Average Diluted Shares Outstanding | 7.71% | 10.93% | 14.36% | 13.81% | 12.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |